ConductScience.org, home

Trial · NCT02379637

Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough

NCT02379637, Phase 2, Completed, Novartis; results first posted 2016-07-11

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough. Trials, record NCT02379637. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02379637

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
NCT number
NCT02379637
Status
Completed
Phases
Phase 2
Enrollment
70 participants, actual
Lead sponsor
Novartis
Conditions
Common Cold Associated With Cough
Interventions
N-acetylcysteine, Placebo
First posted
2015-03-05
Last updated
2016-07-11
Results first posted
2016-07-11

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryCough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)72 hoursNumber of coughs will be measured by a 24-hour ambulatory cough monitoring system for the first 72 hours
SecondarySafety of Daily Dose of NAC (Number of Patients With Adverse Advents)7 DaysNumber of patients with adverse advents

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYCough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)72 hoursFull Analysis setlog-transformed total cough countMEAN
SECONDARYSafety of Daily Dose of NAC (Number of Patients With Adverse Advents)7 DaysparticipantsNUMBER

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)A N-acetylcysteine6.92Standard Deviation 0.95log-transformed total cough count
Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours)B Placebo6.51Standard Deviation 0.83log-transformed total cough count
Safety of Daily Dose of NAC (Number of Patients With Adverse Advents)A N-acetylcysteine4participants
Safety of Daily Dose of NAC (Number of Patients With Adverse Advents)B Placebo4participants

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDA N-acetylcysteine35
Overall StudySTARTEDB Placebo35
Overall StudyCOMPLETEDA N-acetylcysteine33
Overall StudyCOMPLETEDB Placebo34
Overall StudyNOT COMPLETEDA N-acetylcysteine2
Overall StudyNOT COMPLETEDB Placebo1

Adverse events2

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherDyspepsiaGastrointestinal disordersA N-acetylcysteine2352
otherDyspepsiaGastrointestinal disordersB Placebo2352

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityA N-acetylcysteine
Total, all-cause mortalityB Placebo
Total, other adverse eventsA N-acetylcysteine235
Total, other adverse eventsB Placebo235
Total, serious adverse eventsA N-acetylcysteine035
Total, serious adverse eventsB Placebo035

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource
A N-acetylcysteine vs B Placebo: Safety of Daily Dose of NAC (Number of Patients With Adverse Advents)Trial comparisons
A N-acetylcysteine vs B Placebo: serious adverse eventsTrial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02379637

GET https://conductscience.org/api/trials/v1/NCT02379637/registered